SecBot SecBot
S-4/A ·Filed Sep 4, 2026

PULM

Pulmatrix, Inc.
BEARISH
Impact 7/10
Horizonweeks Processed2mo ago SEC0001493152-26-041607
Actionable Insight ▼ Bearish

The merger is a binary event for PULM holders. The stock will likely trade on the probability of deal closure and the perceived value of Eos's preclinical pipeline. Monitor the special meeting vote on October 2 and any updates on Eos's $13M+ financing condition. Post-merger, the combined company's stock (MTXL) will be a high-risk, pre-revenue biotech play focused on gerotherapeutics.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$1.40
T+0 close · Sep 4, 2026 · via day close
Latest settled
+2.51%
T+20 · $1.43 · next T+60 in 15d
Vs SPY
+0.79%
α at T+20
Latest observation
+5.14%
T+48 · FF3 residual α
  1. T+0 · Sep 8 $1.40entry
  2. T+1 · 2mo ago +6.09%α +6.56% · $1.48
  3. T+5 · 2mo ago +3.58%α +4.70% · $1.45
  4. T+20 · 6w ago +2.51%α +0.79% · $1.43
  5. T+49 · todayOpen
  6. T+60 · in 15d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pulmatrix filed Amendment No. 2 to its S-4 registration statement, advancing the proposed reverse merger with Eos SENOLYTIX. The filing sets a special stockholder meeting for October 2, 2026, to vote on key proposals including share issuance for the merger (which would dilute current PULM holders to ~6% of the combined company), a reverse stock split, and an authorized share increase. The merger is a transformative event that will effectively transfer control to Eos, with the combined company to be renamed Eos SENOLYTIX Inc. and trade under 'MTXL', but existing PULM holders face massive dilution and the combined entity is a pre-revenue biotech with significant execution risk.

Key Facts

  • Pulmatrix stockholders will own approximately 6% of the combined company post-merger, with Eos securityholders owning ~94%.
  • The special meeting is scheduled for October 2, 2026, to vote on the merger, reverse stock split (1:2 to 1:10), and authorized share increase from 200M to 250M shares.
  • Eos must receive at least $13M in gross cash proceeds from financing transactions as a condition to closing.
  • The combined company will be a 'controlled company' with SENOTHERAPEUTIX, Inc. expected to own >50% voting power.
  • Pulmatrix reported a net loss of $5.2M in 2025 and had $2.2M cash as of June 30, 2026, with substantial doubt about its ability to continue as a going concern without the merger.

Financial Impact

Current PULM holders diluted to ~6% of combined entity; implied value of Pulmatrix's 6% interest is ~$7.85M based on a $100M pre-money valuation for Eos plus $19M in capital. Pulmatrix had $2.2M cash as of June 30, 2026.

dilutioncashownership

Risk Factors

  • Massive dilution: current PULM holders will own only ~6% of the combined company.
  • Merger may not close if stockholder votes or financing conditions are not met; Pulmatrix has going-concern risk without the deal.
  • Combined company is pre-revenue with preclinical assets (PTC-2105) facing high clinical development risk.
  • Controlled company structure gives SENOTHERAPEUTIX majority voting power, limiting minority shareholder influence.
  • Nasdaq listing of combined company (MTXL) is conditional on meeting initial listing standards, including a $4.00 bid price after reverse split.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 11 SEC documents filed with EDGAR.

DocumentAccession Number
S-4/A Filing (PULM), Batch item 10001493152-26-041607
Exhibit: ex4-7.htm0001493152-26-041607
Exhibit: ex5-1.htm0001493152-26-041607
Exhibit: ex99-5.htm0001493152-26-041607
Exhibit: ex99-6.htm0001493152-26-041607
Exhibit: ex23-1.htm0001493152-26-041607
Exhibit: ex23-3.htm0001493152-26-041607
Exhibit: ex23-2.htm0001493152-26-041607
Document: 0001493152-26-041607-index-headers.html0001493152-26-041607
Document: 0001493152-26-041607-index.html0001493152-26-041607
Document: 0001493152-26-041607.txt0001493152-26-041607

Track record

21 reports on PULM

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +15.29% at T+60 after the Aug 7, 2026 report. 6 of 7 went positive at some point.

Filters
  1. Nov 9, 20267d ago 425 Neutral 3/10 Entry $1.36 to $1.33 Now $1.33 −1.85% ▼ −1.84% −0.15% vs SPY
  2. Oct 30, 202617d ago 425 Neutral 3/10 Entry $1.40 to $1.38 Now $1.33 −5.00% ▼ −1.43% +1.27% vs SPY
  3. Oct 23, 202625d ago EFFECT Bearish 5/10 Entry $1.48 to $1.40 Now $1.33 +10.14% ▲ +5.41% +4.85% vs SPY
  4. Oct 22, 202625d ago 425 Neutral 4/10 Entry $1.42 to $1.41 Now $1.33 −6.34% ▼ −0.70% −1.41% vs SPY
  5. Oct 13, 20264w ago 425 Neutral 4/10 Entry $1.38 to $1.43 Now $1.33 −3.62% ▲ +3.62% +4.77% vs SPY
  6. Oct 7, 20265w ago DEFA14A Neutral 2/10 Entry $1.53 to $1.41 Now $1.33 −12.91% ▼ −7.67% −7.39% vs SPY
  7. Oct 2, 20266w ago S-3/A Bearish 5/10 Entry $1.48 to $1.43 Now $1.33 +10.14% ▲ +3.38% +3.80% vs SPY
  8. Sep 28, 20267w ago EFFECT Bearish 5/10 Entry $1.59 to $1.48 Now $1.33 +16.35% ▲ +6.92% +8.12% vs SPY
  9. Sep 25, 20267w ago DEFM14A Bearish 6/10 Entry $1.59 to $1.48 Now $1.33 +16.35% ▲ +6.92% +8.12% vs SPY
  10. Sep 23, 20267w ago S-4/A Neutral 2/10 Entry $1.67 to $1.54 Now $1.33 −20.36% ▼ −7.78% −7.37% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 4, 2026